Fig. 1: Clinical course, survival outcomes and post-transplant non-relapse mortality in patients with DDX41 mutated MDS or AML. | Bone Marrow Transplantation

Fig. 1: Clinical course, survival outcomes and post-transplant non-relapse mortality in patients with DDX41 mutated MDS or AML.

From: Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia

Fig. 1

a Swimmer’s plot showing clinical course of patients with or without alloSCT. Among the non-alloSCT cohort, 11 (68.75%) patients with persistent/progressive disease were alive at last follow-up. In contrast, all five patients who died after alloSCT were in complete remission before alloSCT. b Overall survival since diagnosis comparing patients undergoing alloSCT to those without alloSCT. c Cumulative incidence of non-relapse mortality (NRM) and relapse. Abbreviations: HMA hypomethylating agent, IC intensive chemotherapy, IMID immunomodulator.

Back to article page